NRAS and leukemia: Of additional interest, isocitrate dehydrogenase (IDH) gene mutations have been shown to initiate the development of AML by cooperating with oncogenic FLT3 or NRAS. IDH mutant AMLs showed great sensitivity to JQ1, and western blots of IDH mutant leukemias treated with JQ1 showed a decrease in MYC levels [43].